Licence Transfer Procedure for Medical Device Registrations in Myanmar

1. Key takeaways

A transfer of a Myanmar registration certificate does not happen automatically; it must proceed through the Change of Registration application procedure. The precondition for completing the transfer is obtaining a Letter of Release signed and notarised by the original distributor. Together these form a dual linkage of contract documents and administrative procedure: the commercial side of the transfer is settled by paper the parties sign, while the regulatory side is completed only when the authority accepts the application.

GRZAN insight: the real bottleneck in the transfer process usually lies not in the FDA’s approval step but in the negotiation with the original distributor over the Letter of Release. Companies should therefore assess transfer feasibility by shifting the question from whether the application can be approved to whether the original distributor will cooperate. The administrative track is predictable; the commercial track is not, and that asymmetry determines how the feasibility study should be framed.

• Procedure — the licence transfer requires a Change of Registration application filed through the Myanmar FDA e-Submission system’s medical device module.
• Precondition — a fully signed and notarised Letter of Release from the original distributor, to be provided within 14 calendar days of a written request as a practical estimate.
• Continuity — the certificate remains valid for 5 years and the transfer does not reset the validity period.

2. Legal basis

The table below consolidates the regulatory elements of the transfer procedure. It records the form of the application, the key supporting document and its signing requirements, the contractual time limit and remedy that operate as practical estimates, the treatment of the validity period, and the submission channel including the authentication requirement that applies to portal access.

3. Expert insights

Insight 1: the transfer must go through a Change of Registration application, which shows this is a change to the certificate’s content rather than an automatic substitution of the responsible party. The procedural nature of the change determines that materials evidencing the basis for the change must be submitted. The regulator is not informed of a transfer by a commercial contract alone; it requires the change to be presented in the form the change procedure prescribes, with the supporting documents that justify updating the certificate record.

Insight 2: the Letter of Release is the precondition document for the transfer, and it must be notarised. The notarisation requirement gives obtaining the letter both a procedural cost and a time cost. Even where the original distributor is fully willing, the signing and notarisation steps cannot be compressed to zero, so the transfer timeline must include them as fixed elements rather than assuming the letter appears the day it is requested.

Insight 3: a transfer does not reset the five-year validity period. The transferee inherits the remaining validity of the original certificate, which directly affects the assessment of the transfer’s commercial value. A certificate nearing expiry carries a shorter commercial runway than its face value suggests, so the parties should price the transfer on the remaining term rather than on the assumption that a fresh five years begins on completion.

Insight 4: after the transfer, post-market obligations move with the certificate. The new holder takes over the duties of maintaining the list of registered devices, vigilance, and recall. This continuation means the transfer is not only a commercial handover; it shifts live regulatory duties to the incoming holder, and both parties should treat the transition as a compliance handover with documented scope, not merely a change of invoice recipient.

Insight 5: transfer and release letter clauses should be agreed in advance in the first distribution agreement. Negotiating them afterwards carries a significantly higher cost in bargaining. When the parties sign the first agreement their interests are aligned and these clauses cost little; when a transfer is already underway the original distributor holds the key document and the leverage has reversed, which is precisely when the terms are hardest and slowest to obtain.

4. Practical recommendations

• Agree on transfer and release letter clauses in the first distribution agreement. State the obligation, the time limit, and the consequences of breach explicitly.
• Process the transfer through the Change of Registration application procedure. Do not confuse it with an application for a new certificate.
• Obtain the notarised Letter of Release early. Reserve time for the notarisation step within the transfer schedule.
• State the rules on inheriting the validity period in the transfer agreement. Do not assume the validity period resets on transfer.
• Clarify who assumes the post-market obligations after the transfer. Form a written handover record covering the transferred duties.

5. Verification checklist

• □ Confirmed that the registration certificate transfer must go through the Change of Registration application procedure
• □ Agreed on release letter clauses in the first distribution agreement
• □ Obtained the notarised Letter of Release
• □ Clarified the rules on inheriting the validity period
• □ Clarified the party assuming the post-market obligations
• □ Completed the written handover record
• □ Incorporated the registration ledger into management

Regulatory information verified as of 29 October 2026.

In the Southeast Asian market, GRZAN’s core strengths concentrate on three points. First, distinguishing the legislative progress of each ASEAN member state’s dedicated medical device law — Singapore, Malaysia, Thailand, Indonesia, the Philippines, Vietnam and others have each established their own written medical device regulatory framework, whereas Myanmar has not yet enacted a dedicated law; its rules are assembled from three layers: the technical framework of the ASEAN Medical Device Directive, administrative guidance from the competent authority, and the catch-all authorisation of the Public Health Law 1972, so compliance certainty is markedly lower than in markets where dedicated legislation is complete. Second, local authorised representative services, in which GRZAN can act as the statutory representative of the manufacturer in these countries, carrying registration submissions, regulatory communications, and post-market reporting obligations. Third, quality system and laboratory testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com